Paclitaxel tocopheryl-based emulsion - Sorrento Therapeutics
Alternative Names: IG 004; IG-002; paclitaxel TPGS-based emulsion; QW 8184; S 8184; Tocosol paclitaxelLatest Information Update: 05 Nov 2023
At a glance
- Originator Sonus Pharmaceuticals
- Developer Sorrento Therapeutics
- Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Tubulin modulators; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bladder cancer; Breast cancer; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
Most Recent Events
- 23 Nov 2016 Discontinued - Preclinical for Solid tumours (New delivery system) in USA (IV) (Sorrento Therapeutics pipeline, November 2016)
- 08 Apr 2014 Further analyses of adverse events data from a phase III trial in Breast cancer presented at the 105th Annual Meeting of the American Association for Cancer Research (AACR-2014)
- 31 Dec 2013 Preclinical trials in Solid tumours (TPGS-based nanoparticle emulsion) in USA (IV)